Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
KLHDC2
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "KLHDC2" in MCE Product Catalog:
Cat. No.: HY-174218
Target:
Research Areas:
KLHDC2 ligand 1 is an E3 ligase ligand. KLHDC2 ligand 1 can be used for synthesis of PROTAC BRD4 Degrader-31 (HY-174210) .
Cat. No.: HY-157558
Synonyms: 8SGE
Target:
Research Areas:
KDRLKZ-1 (8SGE) is a small-molecule ligand of KLHDC2 E3 ligase (Kd = 0.36 μM), with an IC50 of 0.21 μM and 0.31 μM in alphaLISA and TR-FRET assays, respectively. KDRLKZ-1 binds to the substrate-binding pocket of the KLHDC2 kelch domain, mimics the interaction of natural substrates and displaces them. KDRLKZ-1 acts as an oligomer disruptor, regulates the oligomerization of the KLHDC2-EloB-EloC complex, and induces the dissociation of tetramers into smaller components. KDRLKZ-1 can be used in scaffold ligand research for PROTAC degraders targeting KLHDC2 .
Cat. No.: HY-168535
CAS No.: 1010913-79-7
Target:
Research Areas:
SJ6145 is a potent ligand for KLHDC2 SBD, with the Kd of 16.9 μM in SPR test, IC50 value of 42 μM in inhibiting KLHDC2 SBD binding to a di-Gly degron peptide test .
Cat. No.: HY-168635
Target:
Research Areas:
SJ46420 is a BRD3 PROTAC degrader with a DC50 of 224 nM in U2OS cells. SJ46420 selectively mediates BRD3 degradation, exerts only partial effects on BRD2 and BRD4, and its activity is dependent on KLHDC2. SJ46420 is a prodrug variant of SJ46421 (HY-168634). SJ46420 can be used in the research of prostate cancer .
Cat. No.: HY-157559
Target:
Research Areas:
KDRLKZ-2 is a small-molecule ligand of KLHDC2 E3 ligase (Kd = 95 nM), with an IC50 of 68 nM and 0.1 μM in alphaLISA and TR-FRET assays, respectively. KDRLKZ-2 binds to the substrate-binding pocket of the kelch domain of KLHDC2, mimics the interaction of natural substrates and displaces them. KDRLKZ-2 acts as an oligomer disruptor, regulates the oligomerization of the KLHDC2-EloB-EloC complex, and induces the dissociation of tetramers into smaller components. KDRLKZ-2 can be used in scaffold ligand studies of PROTAC degraders targeting KLHDC2 .
Cat. No.: HY-RS07348
Target:
Research Areas:
KLHDC2 Human Pre-designed siRNA Set A contains three designed siRNAs for KLHDC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-174208
CAS No.: 1005275-19-3
Target:
Research Areas:
KLHDC2-IN-1 (Compound 6) is a ligand targeting the ubiquitin E3 ligase KLHDC2 (Kd: 160 nM). KLHDC2-IN-1 enables the synthesis of a PROTAC that can effectively degrade BRD4 in cells .
Cat. No.: HY-157491
CAS No.: 3093556-90-9
Research Areas:
K2-B4-5e is a BRD4 PROTAC degrader with a DC50 of 6.2 nM . K2-B4-5e triggers the degradation of BRD4 and BRD2 mediated by KLHDC2 in a ubiquitin-proteasome system-dependent manner. K2-B4-5e induces BRD4 degradation in mouse cells. K2-B4-5e can be used in research related to prostate cancer, breast cancer and osteosarcoma [2].
Cat. No.: HY-168634
Target:
Research Areas:
SJ46421 is a BRD3BD2 PROTAC degrader. SJ46421 induces a cooperative ternary complex of KLHDC2 and BRD3BD2 with an IC50 of 7.8 nM. SJ46421 binds to the substrate-binding pocket of KLHDC2, forms cooperative ternary complexes with BRD3BD2, BRD2BD2 and BRD4BD2, disrupts the autoinhibitory tetramer assembly of KLHDC2, drives selective ubiquitination of BRD3BD2, and inhibits the ubiquitination of endogenous KLHDC2 diglycine substrates. SJ46421 can be used in cancer research .
Cat. No.: HY-180280
Target:
Research Areas:
KLHDC2 ligand 3 is an E3 ligase ligand. KLHDC2 ligand 3 can be used for the synthesis of PROTAC CDK6 Degrader 1 (HY-180277) .
Cat. No.: HY-174220
Research Areas:
Boc-Dipiperidine-KLHDC2 ligand 1 is an E3 ligase ligand-linker conjugate that incorporates a KLHDC2 ligand (HY-174218). Boc-Dipiperidine-KLHDC2 ligand 1 can be used for synthesis of PROTAC BRD4 Degrader-31 (HY-174210) .
Cat. No.: HY-180263
Target:
Research Areas:
KLHDC2 ligand 4 (compound KL-3 (8)) is an E3 ligase ligand that can be used for synthesis of PROTAC CDK6 Degrader 2 (HY-180262) .
Cat. No.: HY-180264
Research Areas:
KLHDC2 ligand 4-cyclohexane-CO-pip-cyclobutane is an E3 ubiquitinase ligand-linker conjugate that can be used for synthesis of PROTAC CDK6 Degrader 2 (HY-180262) .
Cat. No.: HY-157560
Synonyms: 1NEG
Target:
Research Areas:
KDRLKZ-3 is a selective E3 ligase. KDRLKZ-3 is a ligand for KLHDC2 with a IC50 value of 4.1 μM in the alphaLISA experiment .
Cat. No.: HY-168646
Target:
Research Areas:
SJ46411-Br is one of CRL2 KLHDC2 targeting Ligands for E3 Ligase. SJ46411-Br can bind to KLHDC2 to form a complex to promote cooperative homologous selective ternary complex formation. SJ46411-Br can be coupled to BET ligand JQ1 (HY-13030) through PROTAC linker to synthesize corresponding PROTACs .
Cat. No.: HY-168536
CAS No.: 3086104-39-1
Target:
Research Areas:
SJ46411 is a potent ligand for KLHDC2, with a Kd of ~260 nM measured by isothermal titration calorimetry (SPR Kd = 0.5 μM, TR-FRET IC50 = 3.9 μM, ΔTm = 6.0 °C) .
Cat. No.: HY-157561
Target:
Research Areas:
K2-B4-3e is a BRD4 PROTAC degrader with a DC50 of 66 nM. K2-B4-3e binds to KLHDC2 to form a ternary complex with BRD4, inducing degradation dependent on the ubiquitin-proteasome system. K2-B4-3e is applicable for cancer-related research [2].
Cat. No.: HY-P703310
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HCA33
Species:
Source:
Cat. No.: HY-180262
PROTAC CDK6 Degrader 2 (compound 48b), the active form of PROTAC CDK6 Degrader 1 (HY-180277), is a potent and selective PROTAC CDK6 degrader that binds strongly to KLHDC2 (KD = 0.005 μM). PROTAC CDK6 Degrader 2 functions through a KLHDC2-dependent and ubiquitin-proteasome-mediated mechanism. PROTAC CDK6 Degrader 2 can be used for cancer research .
Cat. No.: HY-P703461
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HCA33
Species:
Source:
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
